Objective: To assess the efficacy and safety of novel pediatric-appropriate prolonged-release melatonin minitablets (PedPRM) vs. placebo for insomnia in children with autism spectrum disorder (ASD), with or without attention-deficit/hyperactivity disorder (ADHD) comorbidity, and neurogenetic disorders (NGD). 
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INTRODUCTION
Pediatric insomnia is a widespread problem with prevalence of 1-6% in the general pediatric population and 50-75% in children with neurodevelopmental or psychiatric comorbidities, specifically autism spectrum disorder (ASD; including autistic disorder, Asperger's disorder and pervasive developmental disorder) and neurogenetic disorders (NGD, e.g. Rett's disorder, Tuberous Sclerosis, Smith-Magenis syndrome [SMS] and Angelman syndrome). [1] [2] [3] The sleep disturbances exacerbate cognitive performance deficits and behavioral problems and subsequently entire family distress. 4 Current practices recommend parent-directed behavioral sleep interventions as first-line treatment for pediatric insomnia in ASD/NGD with reportedly 25% response rate. 5, 6 Pharmacotherapy is often provided when the behavioral intervention fails. However, despite the severity of sleep problems, there are no medications with regulatory approval for the treatment of insomnia in children and adolescents. 7, 8 Consequently, physicians often prescribe off-label drugs (e.g., antihistamines, alpha-adrenergic agonists [clonidine] , antidepressants, antipsychotics) for their sedative side effects without proven safety, efficacy, or dosing regimen in children. 7 Moreover, unlicensed melatonin preparations or food supplements are used despite considerable concerns over the quality and potential safety hazards. 8, 9 Melatonin (N-acetyl-5-methoxytryptamine) is the primary hormone produced by the pineal gland during nocturnal periods to properly time circadian sleep/wake rhythms and enhance sleepiness. 10 A growing body of evidence indicates abnormal melatonin secretion and circadian rhythmicity in children with neurodevelopmental disorders, specifically ASD, which may explain the abnormal development of sleep/wake cycles, noted since the first year of life; such abnormalities justify the use of melatonin for insomnia in these populations.
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The use of melatonin for treating chronic sleep-wake cycle disorders of children with ASD/NGD is increasing. 5, 12, 14 A recent meta-synthesis concluded that melatonin, behavioral interventions, and parent education/interventions appear the most effective at ameliorating multiple domains of sleep problems.
14 A recent study compared the effect of behavioral intervention and controlled-release melatonin 3 mg on sleep in children with ASD. 15 Whereas this study demonstrated that each treatment alone was beneficial in improving SL and TST, their combination tended to be more effective although not significantly. In another study, children who failed to improve on behavioral intervention alone, immediate release (IR)-melatonin demonstrated beneficial effects on sleep latency (SL) and to a lesser extent on total sleep time (TST). 6 Similarly, a recent open-label, dose escalation study of IR-melatonin reported significant improvement in SL but not TST. 16 As melatonin has a very short half-life (40 minutes), a prolonged-release (PR) melatonin (PRM) formulation, designed to mimic the endogenous profile by releasing M A N U S C R I P T
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3 melatonin throughout the night, may help improve both sleep initiation and maintenance. 13, 17 Despite the increasing use of melatonin in this pediatric population, short-and longterm safety and efficacy controlled studies of melatonin as well as dosing regimen data are lacking. Therefore, there is an unmet need for appropriately tested and approved drugs proven to be effective and safe for insomnia in this population.
A 2mg PRM prescription drug is available in the European Union and other countries for primary insomnia in patients aged 55 years and older (Circadin, Neurim Pharmaceuticals Ltd). 18 If crushed to facilitate swallowing, these tablets lose the controlled-release properties, as the active ingredient is immediately released. 19 A pediatric-appropriate 3mm diameter prolonged release melatonin minitablet (PedPRM) was developed (Neurim Pharmaceuticals Ltd), which can be more easily swallowed by young children.
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The aim of this study was to assess the efficacy and safety of PedPRM vs placebo for insomnia in children with ASD and NGDs who did not improve after 4 weeks of sleep behavioral intervention. We hypothesized that PedPRM will effectively increase TST, an important concern for families of the children. 2, 21 The dosage of melatonin used in the study (dose titration, 2-5 mg/day and up to 10 mg/day) was well within the range reported in children with ASD and NGD. Exclusion criteria included other sleep disorders (e.g., moderate to severe sleep apnea), use of prohibited medication (see Table S1 , available online) or melatonin within 2 weeks prior to screening, allergy to melatonin or lactose, or unresponsive to previous Circadin therapy participation in a clinical trial within the last 3 months prior to the study. Females not M A N U S C R I P T
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using contraceptives who were sexually active, pregnant, and/or breastfeeding were excluded.
Procedures
The study comprised 2 weeks single-blind placebo run-in, a randomized double-blind efficacy and safety study of 13 weeks PedPRM/placebo treatment (completed), followed by open-label treatment (ongoing) comprising 13 weeks PedPRM at final dose (or placebo equivalent dose), 78 weeks PedPRM treatment with optional dose escalation to 10 mg, and 2
weeks single-blind placebo period (withdrawal effects), altogether 2.2 years. Here we report on the double-blind period.
Children without documented history of sleep behavioral intervention at screening underwent 4 weeks of advice booklet-assisted basic parent-led sleep behavioral intervention based on a previously studied and standardized sleep behavior treatment). 22 This period ensured that children whose sleep disorder was amenable to treatment with nonpharmacological intervention were not randomized, and also served as wash-out from any hypnotics. Eligible children entered a 2-week single-blind placebo run-in period after which, 
Study Endpoints
Sleep variables, reported by parent/caregiver, were assessed using a validated SND that has been used in previous trials, including a previous pediatric IR-melatonin trial. 6, 24 The SND was to be completed every morning by the parent/caregiver at home for 14 days prior to Actigraphy monitors (Actiwatch) were included in the study as a secondary objective measurement tool for the primary (TST) and first secondary (SL) sleep parameters.
Actigraphs were dispensed to participants and were worn from drug intake at night until lights on in the morning for 14 nights before Visit 2 and Visit 4.
Statistical Methods
Efficacy analyses are presented for the full analysis subset (FAS), comprising all participants in the safety analysis set (who take at least one dose of study medication) who clonidine by 5.6%, and beta-blockers by 0.8% participants.
Prior melatonin use was reported by 65.6% of the participants (IR 57.6%, CR 4.0%, other 4.0%), but 52.0% had stopped because the melatonin had no effect (22.4%) or for other reasons (29.6%). The rest of the 17 participants (13.6%) were washed out during the behavioural intervention period. No participants reported prior Circadin use. There were no notable differences between the groups for baseline disease characteristics or medications.
Treatment compliance, calculated by returned mini-tablets after 13 weeks of double-blind treatment, was 105.4 ± 21.98% in the PedPRM and 99.7 ± 9.25% in the placebo group.
Principal investigators reported that there was no need to crush the mini-tablets and children were able to swallow the tablets, thus confirming recent study results.
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Efficacy
The study met the primary endpoint demonstrating statistically significant effects of PedPRM vs. placebo on change from baseline in mean SND-assessed TST after 13 weeks of double-blind treatment (Table 2) Change from baseline in mean TST during the double-blind phase is shown in Figure   2A . The improvement in TST and the significant differences between PedPRM and placebo treatment effects were already evident at week 3 (p=.006). In participants who improved on the 2-mg dose after 3 weeks, efficacy was maintained throughout the rest of the 13-week period ( Table 3 ). The increase in TST between weeks 3 and 13 of the double-blind treatment is ascribed to the dose escalation in participants who did not respond to the initial dose.
SND-assessed SL after 13 weeks of double-blind treatment (first secondary outcome) also improved (i.e., decreased) significantly more with PedPRM 2/5 mg than placebo treatment ( Effect size of the treatment (over placebo; FAS, PPP) was 0.52 for both (Table 2) .
Using reduction in SL by ≥15 minutes as a criterion of clinical response 27,29 after 13 weeks, 63.8% of the PedPRM-treated, compared to 32.8% in the placebo-treated group, were responders (Odds ratio 3.83; p=.001, see Table S3 , available online). The difference of 31% between groups corresponds to an NNT of 3.2.
The improvement (decrease) in SL and the significant differences between PedPRM and placebo effects were already evident at week 3 (p=.001, Figure 2B ). In participants who improved on the 2mg dose after 3 weeks, efficacy was maintained throughout the rest of the 13-week period ( Table 3 ). The improvement in SL between weeks 3 and 13 of the doubleblind treatment is ascribed to the dose escalation in participants who did not respond to the initial dose.
Altogether, by the end of the double-blind period, the percentage of participants with TST and/or SL response rate was significantly higher with PedPRM than placebo (68.9% vs 39.3%, p=.001).
Besides shortening of SL, the observed increase in TST could be best explained by a greater improvement (increase) in the LSE compared to placebo (Table 2) .
By the end of the 13-week double-blind period, mean LSE increased on average by 77.93 minutes in the PedPRM-treated, compared to 25.45 in the placebo-treated group ( Table   2 ). The adjusted mean (SE) change from baseline in LSE in the PedPRM-treated (FAS) was Table 2 ). The increase in LSE with PedPRM was present after 3 weeks of treatment and significantly greater than placebo (p=.034).
There were no other statistically significant differences in SND-assessed treatment effects. By the end of the double-blind period, mean bedtime in the PedPRM-treated group was somewhat earlier than in the placebo-treated group but not significantly. Importantly, PedPRM treatment did not induce earlier wakeup; children woke up somewhat later in the PedPRM-treated compared to those in the placebo-treated group but not significantly ( Table   2) .
Subgroup analyses showed similar responses by geographical region (US and Europe) and age groups (2-5 and over 8 years of age). A somewhat higher response in smaller, 6-8 years age group is hard to interpret due to participant small sample size.
Dose Escalation
After 3 
Actigraphy
Despite major efforts to ensure adherence, actigraphy monitoring was challenging in this population, and a majority of participants (75% in the PedPRM and 77% in the placebo group) refused to wear the device during one or both periods and/or took it off some time during the night. Only 12 participants in the PedPRM and 13 in the placebo group had data for both baseline and 13 weeks of treatment, and even in those it was not possible to ascertain The PedPRM-treated group showed a greater improvement (decrease) in total CSDI score compared to placebo-treated group (see Table S4 , available online). The estimated mean (SE) treatment difference for the change from baseline in total CSDI score was -0.95 (0.436) (p=.032) at week 3 and -0.92 (0.511) units (p= .074) at week 13.
In the PedPRM group, there was a significant improvement in CSDI-assessed parents' satisfaction in child sleep pattern (p=.005) and tendencies to benefit in "problem settling"
(p=.054) and "co-sleeping" (p=.067) compared to placebo (see Table S4 , available online).
There were no statistically significant differences between the treatment groups for any of the remaining CSDI subscores.
Safety Evaluation
During the double-blind phase, treatment-emergent AEs (TEAEs) were reported by 51 (85.0%) participants in the PedPRM-treated (202 events) and 50 (76.9%) participants in the placebo-treated group (159 events) (see Table S5 , available online). Most of these TEAEs were similar between groups and known symptoms in children with ASD (e.g., agitation, mood swings) or generally in children (e.g., upper respiratory tract infection, cough, dyspnea, vomiting). Nervous system disorders were more common in the PedPRM-treated group (41.7% vs 21.5%); the difference was mainly driven by somnolence and headache, which were more common in the PedPRM-treated group. TEAEs judged by the clinician as treatment-related occurred in 12 (20.0%) participants in the PedPRM and 11 (16.9%) in the placebo group (28 and 20 events respectively) (see Table S6 , available online). Somnolence, an expected AE of PRM, was more commonly reported in the PedPRM than placebo group.
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During the double-blind phase, severe events were reported by 13 (21.7%) participants in the PedPRM and 13 (20.0%) participants in the placebo group, with similar patterns (see Table S7 , available online). One patient in the PedPRM group discontinued due to non-serious AEs (fatigue, agitation, and stereotypy). One patient in the placebo group temporarily discontinued due to 2 SAEs (pneumonia and respiratory tract infection viral) and one non-serious AE (tachypnea).
There were no notable differences between PedPRM and placebo for mean changes in blood pressure, pulse rate, respiratory rate, or temperature. Overall, there were no clinically significant differences between PedPRM and placebo for weight, height, or BMI. At baseline, the Tanner assessments of pubertal development showed a greater proportion of participants in the placebo group were preadolescent compared to the PedPRM group, reflecting the slightly lower age of participants in the placebo group (mean age 8.4 versus 9.0 years). In the 13-week double-blind phase, there was no apparent difference between PedPRM and placebo in change from baseline for SD scores of pubic hair, breast, and genitalia development.
Of 16 participants with a history of epilepsy in the study, only one had experienced a M A N U S C R I P T
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seizure (non-serious absence seizure) and this was during placebo treatment.
DISCUSSION
This randomized placebo-controlled study showed that in children with ASD, a pediatric-appropriate PRM was more effective than placebo in increasing TST, the primary endpoint of this study, and reducing SL. Both these beneficial actions of PedPRM on sleep were established by 3 weeks and maintained throughout the 13 weeks of treatment.
Importantly, the drug was similarly effective in children with or without ADHD comorbidity.
No unexpected safety issues were reported. Adverse effects were few and mild, with only headaches and daytime somnolence increased in the treatment group relative to placebo group, and there was no increase in or new onset of seizures. In contrast to the usual difficulties with tablet formulations experienced by children with ASD, compliance was excellent without the need to crush or dissolve PedPRM (which would negate the prolongedrelease properties). In the study of IR-melatonin, a proportion of children on melatonin fell asleep quicker but started to wake earlier, and as a result, the mean improvement in TST in that study was shorter than the improvement in SL. 6 In our study, children on melatonin fell asleep quicker but did not wake up earlier, and as a result, the mean improvement in TST was longer than the improvement in SL, compatible with the prolonged-release nature of this formulation. The earlier onset and wakeup of children treated with IR-melatonin suggested an unwarranted advance of the sleep-wake cycle phase. This doesn't occur with PedPRM, which M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT
11 provides a prolonged melatonin action from the earlier through the later hours of the night.
Another difficulty with some melatonin formulations has been the gradual loss of effect of exogenous melatonin ascribed in part to poor CYP1A2 metabolism, resulting in sustained levels of melatonin in these participants. 30 We did not see any attrition of effect during the initial 3 months of this study, and this will be an important factor to study during the open-label extension phase.
This study included well-accepted and widely used subjective and objective sleep measurement tools. Dose escalation was systematic, and when the open-label results are later reported, this will be the longest robust study of melatonin in this population to date.
This study chose to explore an important explanatory, often neglected, sleep outcome LSE and showed that participant increase in LSE by 77.9 minutes in the PedPRM on average compared to 25.4 minutes in the placebo group was a key contributor to the increase in TST.
Despite our efforts to maximize compliance with actigraphy, one of our secondary outcomes, we encountered implementation difficulties, as reported in other studies with this population. In fact, data from only one quarter of the children studied were informative.
Future trials should consider non-contact forms of objective sleep monitoring in these populations.
Although the study had to span two distinct geographical regions (US and Europe), and participants with and without comorbid ADHD, the investigational drug PedPRM was found equally effective regardless of location or ADHD.
The age group covered in this study was wide, but we found similar benefits in younger and older patient subgroups (2-5-year-olds and children over 8 years of age).
These data indicate that PedPRM (once-daily 2 mg or 5 mg dose) was effective and Note: FAS = full analysis set; MMRM = mixed-effects model for repeated-measures; SE = standard error; TST = total sleep time. Note: PedPRM = pediatric-appropriate prolonged-release melatonin minitablets.
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a List includes TEAEs reported by ≥10% patients in any group. Note: PedPRM = pediatric-appropriate prolonged-release melatonin minitablets.
a AEs reported as treatment-related by ≥5% patients in any group. 
